It can be used as both injection-type or oral-type drug.[9] The marketing authorization in EU was granted on 8 February 2018.[10] It is still under review by regulatory authorities in Japan, pending approval.[11] ------------------------------------- Reported by Jules Levin AASLD 2018 Nov 9-13 SF Philip N Newsome1 ,2, Stephen A Harrison3, Sren Rasmussen4, Tea Monk Fries4, Luc Van Gaal5 1National Institute for Health Research Birmingham Biomedical Research Centre and Liver Unit at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
LegitScript certified and HIPAA compliant, with four named pharmacy partners, medical providers with verifiable NPI numbers made public, and a real San Diego address
At first, they were diabetes drugs
The predominant complaints were nausea, vomiting and diarrhoea
For best results, follow the recommended usage on the package or consult with a healthcare professional